Most Read Articles
Pearl Toh, 28 Aug 2017
Taking long-chain omega-3 fatty acids (LC-OM3) supplements, mainly EPA* and DHA** omega-3s, was associated with a modest but significant reduction in cardiac death risk, according to a meta-analysis of randomized controlled trials (RCTs).
Rachel Soon, 01 Sep 2018

MIMS Pharmacist presents an overview of a standardized extract of Pinus pinaster bark, and its potential role in slowing down the progression of diabetic retinopathy.

Dr. Lau Hui Ling, 01 Aug 2017
Oral contraceptive selection should be individualized for each patient to yield maximum benefit.
18 Apr 2016
Copper intrauterine device exhibited superior efficacy to injectable progestin contraception in women attending termination of pregnancy services in South Africa, according to a pragmatic, open-label, parallel arm, randomised controlled trial.

Prereactivation propranolol reduces PTSD symptoms

14 May 2018
Mind training is the key to prevent PTSD among emergency responders handling trauma cases

Prereactivation propranolol, a treatment protocol suggested by reconsolidation theory, shows potential in reducing symptoms of post-traumatic stress disorder (PTSD), a recent study has shown.

There was a statistically significant 11.50 estimated group difference in post-treatment Clinician-Administered PTSD Scale (CAPS) score, adjusted for pretreatment values (analysis of covariance). The within-group pre- to post-treatment effect sizes (Cohen’s d) were 1.76 and 1.25 for propranolol and placebo, respectively.

The mixed linear model’s estimated time-by-group interaction for the patient-rated PTSD Checklist–Specific (PCL-S) generated an average decrease of 2.43 points per week. The total significant difference was 14.58 points above that of placebo. The pre- to post-treatment effect sizes were 2.74 and 0.55 for propranolol and placebo, respectively.

Analyses per protocol revealed similar significant results for both outcomes.

A total of 60 adults diagnosed with long-standing PTSD were included in this 6-week, double-blind, placebo-controlled, randomized clinical trial. The investigators administered propranolol or placebo 90 minutes before a brief memory reactivation session, once a week for 6 consecutive weeks.

They hypothesized a significant treatment effect of trauma reactivation with propranolol vs trauma reactivation with placebo in reducing PTSD symptoms on both the CAPS and PCL-S in an intention-to-treat analysis.

“Replication studies using a long-term follow-up in various trauma populations are required,” the investigators said.

A noradrenergic beta-receptor, propranolol has been used in this study as a putative reconsolidation blocker to reduce PTSD symptoms, they noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 28 Aug 2017
Taking long-chain omega-3 fatty acids (LC-OM3) supplements, mainly EPA* and DHA** omega-3s, was associated with a modest but significant reduction in cardiac death risk, according to a meta-analysis of randomized controlled trials (RCTs).
Rachel Soon, 01 Sep 2018

MIMS Pharmacist presents an overview of a standardized extract of Pinus pinaster bark, and its potential role in slowing down the progression of diabetic retinopathy.

Dr. Lau Hui Ling, 01 Aug 2017
Oral contraceptive selection should be individualized for each patient to yield maximum benefit.
18 Apr 2016
Copper intrauterine device exhibited superior efficacy to injectable progestin contraception in women attending termination of pregnancy services in South Africa, according to a pragmatic, open-label, parallel arm, randomised controlled trial.